Navigation Links
VeriMed Introduces RADAR(SM): The First Patient Risk Assessment Empowering Pain Physicians To Identify Patients Who May Abuse Or Divert Prescription Drugs
Date:12/3/2013

CHARLOTTE, N.C. and NEW YORK, Dec. 3, 2013 /PRNewswire/ -- VeriMed, a company that has developed technologies to create a safer and more transparent supply chain for controlled substances, today announced the launch of its Risk Assessment of Diversion and Aberrancy (RADARSM), a psychometric assessment that evaluates a patient's risk of abusing or diverting (i.e. selling) prescription medication.

Historically, pain physicians have used assessments that have focused mainly on a patient's likelihood to abuse controlled substances but not their likelihood to exhibit deceptive or manipulative behavior – characteristics that VeriMed believes are at the heart of diversion. RADARSM identifies three specific diversion classifications and six aberrancy categories, providing the physician with a broad baseline of critical information prior to the patient entering the examination room.

"There is a prescription drug epidemic in the U.S., and doctors have become increasingly exposed to the liability of prescribing medication to patients who will abuse and/or divert medication," said Philip E. Gaucher Jr., founder and CEO, VeriMed. "RADARSM gives physicians a picture of a patient's relationship with their medication, offering vital patient information prior to the physician writing a prescription."

"RADARSM provides a snapshot of a patient's mental health, helping doctors validate those patients who are good candidates for pain medication and are perhaps less likely to abuse or divert prescription drugs. By helping reduce exposure to liability, RADARSM allows physicians to focus on providing the best possible care rather than spending time attempting to figure out whether a patient is being truthful regarding his or her needs," said Dr. Michael Trombley, chief medical officer of Pain Management Providers in North Carolina, a beta test participant.

VeriMed has developed six parallel versions of RADARSM to reduce a patient's ability to memorize content from earlier tests and intentionally cheat (known as a carry-over effect). A random, five-minute, non-repetitive version of RADARSM is completed electronically each time a patient visits his or her physician. To create RADARSM, VeriMed partnered with Dr. Carina Fiedeldey-Van Dijk, president of ePsy Consulting, who is a renowned research psychologist specializing in the development and validation of psychometric assessments.

Currently, there are five pain management centers in North Carolina and Tennessee, with a total of 4,000 patients, beta testing RADARSM.

RADARSM is an important component of the overall VeriMed solution. The information collected from RADARSM, in conjunction with other critical patient data, is aggregated into the VeriMed Information Portal, which uses data analytics to flag patients at risk for abuse or diversion. Once the physician has decided to prescribe medication, he or she can then send the prescription to be filled at the VeriMed Pharmacy, where pharmacists also have access to the Information Portal data to fulfill their corresponding responsibility per the Controlled Substances Act of 1970. Finally, if a patient is determined to be a risk, the physician can request that the pharmacist dispense the medication in the VeriPak™, which provides a timestamp when medication is removed. 

About VeriMed
VeriMed has developed technologies to create a more secure and transparent supply chain for controlled substances. Through VeriMed's mix of proprietary technology and services, stakeholders along the controlled substances supply chain, including providers/doctors, wholesalers and pharmacists, may have access to HIPAA-compliant patient data that can be used to help mitigate the risk of substance abuse and drug diversion. There are four components to the VeriMed System: the VeriMed Information Portal, the VeriMed Patient Risk Assessment, the VeriMed Pharmacy and the VeriPak™. 

VeriMed was founded by Philip E. Gaucher Jr. Mr. Gaucher, an entrepreneur with a proven track record, was most recently co-founder of Shale-Inland, an industrial conglomerate with approximately $750 million in annual revenue.

Contact:
Danielle DeVoren / Renatta Siewert
212.896.1272 / 212-896-1251
ddevoren@kcsa.com / rsiewert@kcsa.com


'/>"/>
SOURCE VeriMed
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Konica Minolta Introduces Hand-Held, Real-Time Ultrasound for Use at the Point of Care
2. Smith & Nephew introduces powerful new e-learning platform
3. Kimberly-Clark* Introduces New KimVent* MICROCUFF* Subglottic Suction Endotracheal Tube
4. Smith & Nephew Introduces Advanced Biocomposite Material for Use in Arthroscopic Surgery
5. NxStage Medical Introduces New Products at 2013 American Society of Nephrology Meeting
6. CA BOTANA Introduces SEA ENZYME CALIFORNIA BOTANICAL HAIR SERUM
7. ViGene Biosciences Introduces Worlds Largest Collection of Pre-Made Human Full-Length cDNA ORF and miRNA Adenoviruses
8. Global Vision Introduces New High-Speed Booklet Inspection Technology
9. HOPA Introduces Scope Of Hematology/Oncology Pharmacy Practice
10. RF Technologies Introduces New CodeWatch Designs for Wandering Management Solution
11. Elsevier Introduces SimChart for the Medical Office, a Hands-on EHR to Teach Medical Assistant Students Electronic Documentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing ... this week,s Orlando Dermatology Aesthetic & Clinical (ODAC) Conference, which ... inflammation. The data will be shared in a ... at ODAC, which is being held Jan. 13-16 in ... ...
(Date:1/12/2017)...   TyrNovo , s NT219 drug candidate ... cancer drug resistance and would be ... NT219 is a novel proprietary ... ( IRS1/2 and STAT3) highly involved in ... .   NT219 has demonstrated ...
(Date:1/12/2017)... -- "Global Lung Cancer Vaccine Market & Pipeline ... trends in the global lung cancer vaccine market. ... available in the market. This report analyzes the ... in clinical pipeline and gives comprehensive clinical insight ... the lung cancer vaccines. Currently there are 9 ...
Breaking Medicine Technology:
(Date:1/13/2017)... ... January 13, 2017 , ... The 18th European Congress: Perspectives in ... March 3-4, 2017. This Congress is expertly designed to meet the educational needs ... with lung cancer. , Chaired by Dr. Giorgio V. Scagliotti, Professor of Oncology at ...
(Date:1/13/2017)... ... ... inventor from Pahrump, Nev., used an unsavory medical experience to think of a way to ... urine bag for a half year due to lazy bladder," he said. "Keeping these things ... better way to do this." , He then designed and created a prototype of the ...
(Date:1/13/2017)... , ... January 13, 2017 , ... Friday, January 13 ... of the game room, increasing the size of the location to 90,000 square feet. ... 8-hole mini golf course that takes customers on an educational tour of the historic ...
(Date:1/13/2017)... ... January 13, 2017 , ... As the nation watches this month’s transition ... colleges and schools of education across the country is urging a fundamental reconsideration of ... Principles released today, 175 deans sounded the alarm: “Our children suffer when we deny ...
(Date:1/13/2017)... ... January 13, 2017 , ... One way to obtain a green card is ... can show their work is in the national interest. There are two significant advantages ... be sponsored by an employer; and 2) the submission is made directly to the ...
Breaking Medicine News(10 mins):